Table 1. Composition, particle size, and encapsulation efficiency (EE) of lycopene-loaded SLNs and blank SLNs formulation.
| Formulation No | Lipid type and concentration (g) | Lycopene concentration (g) |
Oil phase
surfactant concentration a (g) |
Aqueous phase
surfactant concentration b (g) |
Particle
size(nm) |
Dispersity index (DI) |
Encapsulation
Efficiency (EE%) |
Drug
Loading (DL,mg/g) |
| Blank SLNs | - | - | - | - | - | - | - | - |
| F1 | Precirol (0.55) | - | 0.01 | 0.52 | 153 ± 6.13 | 0.658 ± 0.131 | - | - |
| F2 | Precirol (0.75) | - | 0.05 | 0.65 | 124 ± 5.24 | 0.382 ± 0.142 | - | - |
| F3 | Compritol (0.55) | - | 0.07 | 0.55 | 162 ± 4.24 | 0.832 ± 0.121 | - | - |
| F4 | Compritol (0.75) | - | 0.10 | 0.62 | 139 ± 3.13 | 0.927 ± 0.128 | - | - |
| Lycopene-SLNs | - | - | - | - | - | - | - | - |
| F5 | Precirol (0.59) | 0.053 | 0.01 | 0.48 | 162 ± 7.01 | 0.444 ± 0.109 | 94 ± 0.2 | 51.8 ± 0.45 |
| F6 | Precirol (0.62) | 0.049 | 0.06 | 0.55 | 155 ± 5.34 | 0.502 ± 0.151 | 96.7 ± 0.4 | 46.7 ± 0.39 |
| F7 | Precirol (0.65) | 0.052 | 0.09 | 0.69 | 125 ± 3.89 | 0.159 ± 0.105 | 98.4 ± 0.5 | 44.8 ± 0.46 |
| F8 | Compritol (0.60) | 0.048 | 0.01 | 0.44 | 166 ± 1.83 | 0.177 ± 0.221 | 86.6 ± 0.6 | 49.5 ± 0.63 |
| F9 | Compritol (0.67) | 0.049 | 0.06 | 0.53 | 143 ± 3.89 | 0.253 ± 0.105 | 89.5 ± 0.3 | 47.6 ± 0.29 |
| F10 | Compritol (0.73) | 0.054 | 0.09 | 0.71 | 129 ± 1.83 | 0.177 ± 0.221 | 93.1 ± 0.6 | 44.4 ± 0.33 |
Data are expressed as mean ± SD (n=3).
a: Tween 80 and b: Poloxamer 407 was used as the oil phase and aqueous phase surfactant in all formulations, respectively. 0.3% (w/w) myristic acid also was used in all formulation.